Dr Reddy's Laboratories: Number of Employees 2012-2026 | RDY
Interactive chart of Dr Reddy's Laboratories (RDY) annual worldwide employee count from 2012 to 2026.
- Dr Reddy's Laboratories total number of employees in 2025 was 27,811, a 2.82% increase from 2024.
- Dr Reddy's Laboratories total number of employees in 2024 was 27,048, a 4.58% increase from 2023.
- Dr Reddy's Laboratories total number of employees in 2023 was 25,863, a 4.31% increase from 2022.
- Dr Reddy's Laboratories total number of employees in 2022 was 24,795, a 9.04% increase from 2021.
| Dr Reddy's Laboratories Annual Employee Count | |
|---|---|
| 2025 | 27,811 |
| 2024 | 27,048 |
| 2023 | 25,863 |
| 2022 | 24,795 |
| 2021 | 22,739 |
| 2020 | 21,650 |
| 2019 | 21,966 |
| 2018 | 23,524 |
| 2017 | 22,671 |
| 2016 | 22,175 |
| 2015 | 20,373 |
| 2014 | 18,421 |
| 2013 | 16,617 |
| 2012 | 15,200 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $11.109B | $3.811B |
| Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |